{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:13Z","timestamp":1793656513925,"version":"4.5.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Idecabtagene vicleucel (ide-cel) was the first US Food and Drug Administration\u2013approved chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM). However, because clinical trials are highly selective with stringent eligibility criteria, the objective of this study was to evaluate the safety and effectiveness of standard-of-care (SOC) ide-cel in the real world. Using the Center for International Blood and Marrow Transplant Research registry, we evaluated 821 patients who received SOC ide-cel. Median follow-up was 11.6 months. Median age was 66 years, and the cohort included 31% patients aged \u226570 years, with 15% Black and 7% Hispanic, and 77% of patients with \u22651 significant comorbidity. The median number of prior lines of therapy was 7, 15% patients previously received B-cell maturation antigen\u2013directed therapy, 17% had extramedullary disease, and 27% had high-risk cytogenetics. Overall response rate was 73%, and complete response rate was 25%. Median progression-free survival was 8.8 months. Treatment-related mortality was reported in 6% of patients. Cytokine release syndrome was diagnosed in 80% of patients (grade \u22653, 3%). Immune effector cell\u2013associated neurotoxicity syndrome was observed in 28% (grade \u22653, 5%), with no cases of Parkinsonism reported. Clinically significant infections were seen in 45% of patients. Second primary malignancies were reported in 4%, including 1% myeloid malignancies. This is, to our knowledge, the largest real-world study of ide-cel CAR-T therapy in patients with relapsed\/refractory (R\/R) MM. We observed a favorable safety and efficacy profile that mirrors trial experience, even in the setting of significant comorbidities in 77% of patients, many of which would have made them ineligible for the registrational KarMMa clinical trial. This trial was registered at www.clinicaltrials.gov as #NCT03361748.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026216","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:12:27Z","timestamp":1744128747000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"first","affiliation":[{"name":"1Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Kansas University Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman Salim","family":"Akhtar","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"5Division of Biostatics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Oloyede","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bye","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Hansen","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[{"name":"7Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devender","family":"Dhanda","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith","family":"Gowda","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"11Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[{"name":"11Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu-Sayeef","family":"Mirza","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Patwardhan","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"12Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[{"name":"11Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"12Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"13Houston Methodist Neal Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2025071011262405000_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"2025071011262405000_bib2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2025071011262405000_bib3","first-page":"3473","article-title":"CAR T-cell therapy: is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv"},{"issue":"18","key":"2025071011262405000_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"2025071011262405000_bib5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.6004\/jnccn.2023.7100","article-title":"Integrating immune therapies for the treatment of multiple myeloma","volume":"21","author":"Mikkilineni","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2025071011262405000_bib6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2025071011262405000_bib7","unstructured":"Data Protection and Privacy, CIBMTR. CIBMTR Annual Reports. 2023. Accessed March 2024. https:\/\/cibmtr.org\/CIBMTR\/About\/Administrative-Reports."},{"issue":"8","key":"2025071011262405000_bib8","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025071011262405000_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2025071011262405000_bib10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025071011262405000_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025071011262405000_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2025071011262405000_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025071011262405000_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood-2023-178933","article-title":"Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): updated analysis from KarMMa-3 [abstract]","volume":"142","author":"Rodr\u00edguez Otero","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025071011262405000_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2025071011262405000_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025071011262405000_bib17","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S2152-2650(23)01626-9","article-title":"P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy [abstract]","volume":"23","author":"Einsele","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025071011262405000_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2025071011262405000_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10297","key":"2025071011262405000_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2025071011262405000_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2025071011262405000_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2025071011262405000_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025071011262405000_bib24","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2023-187565","article-title":"Alternative lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma [abstract]","volume":"142","author":"Midha","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025071011262405000_bib25","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2025071011262405000_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"2025071011262405000_bib27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025071011262405000_bib28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"24","key":"2025071011262405000_bib29","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2025071011262405000_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/167\/2402408\/blood_bld-2024-026216-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/167\/2402408\/blood_bld-2024-026216-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:26:29Z","timestamp":1752161189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/2\/167\/536610\/Standard-of-care-idecabtagene-vicleucel-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026216","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,10]]},"published":{"date-parts":[[2025,7,10]]}}}